{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:13:28Z","timestamp":1788250408554,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent years, Mycoplasma pneumoniae (MP) has developed widespread resistance to macrolide antibiotics, and second-line anti-Mycoplasma drugs such as levofloxacin have begun to be used in children. However, there is currently insufficient data on their efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the application effect of levofloxacin in children with refractory Mycoplasma pneumoniae pneumonia (RMPP) and evaluate its safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is an exploratory research, selecting 82 RMPP patients treated with levofloxacin who were admitted to the Department of Pediatric Respiratory Medicine at Weifang People\u2019s Hospital between November 2023 and December 2024 as the research subjects. Compared the blood routine and biochemical indicators before and after the application of levofloxacin, and observed the clinical efficacy and adverse reactions of levofloxacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The average fever reduction time after the application of levofloxacin was (1.96\u2009\u00b1\u20091.52) days. After the application of levofloxacin, there was no change in white blood cell (WBC), neutrophil (N), platelet (PLT) and other parameters in the blood routine (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). The lymphocyte count (L) has increased but remains within the normal range. There was no difference in alanine aminotransferase (ALT) before and after treatment, but aspartate aminotransferase (AST) decreased compared to before. Lactate dehydrogenase (LDH) and creatine kinase isoenzyme (CKMB) decreased after medication (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), while creatine kinase (CK) remained unchanged. Blood creatinine (CREA) and Blood urea (Urea) both decreased (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), indicating no damage to liver and kidney function. There were a total of 9 adverse drug reactions related to levofloxacin, including 5 cases of rash, 2 cases of gastrointestinal reactions, 1 case of neurological reaction, and 1 case of lower limb pain. No other adverse reactions or sequelae were observed during the 12-month clinical follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Levofloxacin has shown good efficacy in treating RMPP in children, with no serious adverse reactions detected in a short period of time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13433-0","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:47:12Z","timestamp":1777481232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical application and safety observation of levofloxacin in children with refractory Mycoplasma pneumoniae pneumonia"],"prefix":"10.1186","volume":"26","author":[{"given":"Tianhua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"7","key":"13433_CR1","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00431-024-05519-1","volume":"183","author":"G Ding","year":"2024","unstructured":"Ding G, Zhang X, Vinturache A, van Rossum AMC, Yin Y, Zhang Y. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur J Pediatr. 2024;183(7):3001\u201311.","journal-title":"Eur J Pediatr"},{"key":"13433_CR2","first-page":"152e75","volume":"18","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Dou H, Xu B, Xu B, Zhou W, Wang H, Ge L, Hu Y, Han X, Qin X, Li J, Ye L, Wu L, Zuo H, Zhang Q, Liu L, Hu W, Shao J, Yin Q, Han L, Fu X, Dong X, Dong Y, Fu Y, Zhao M, Sun Q, Huo J, Liu D, Liu W, Li Y, Wang Y, Xin D, Shen K. Macrolide resistance of Mycoplasma pneumoniae in several regions of China from 2013 to 2019. Epidemiol Infect. 2024;18:152e75.","journal-title":"Epidemiol Infect"},{"issue":"7","key":"13433_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ijmm.2015.08.021","volume":"305","author":"E Jacobs","year":"2015","unstructured":"Jacobs E, Ehrhardt I, Dumke R. New insights in the outbreak pattern of Mycoplasma pneumoniae. Int J Med Microbiol. 2015;305(7):705\u20138.","journal-title":"Int J Med Microbiol"},{"issue":"3","key":"13433_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/jcpt.13331","volume":"46","author":"FF Dai","year":"2021","unstructured":"Dai FF, Liu FQ, Chen X, Yang J, Wang K, Guo CY. The treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. J Clin Pharm Ther. 2021;46(3):705\u201310.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"13433_CR5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.21037\/apm.2019.10.05","volume":"8","author":"M Lin","year":"2019","unstructured":"Lin M, Shi L, Huang A, Liang D, Ge L, Jin Y. Efficacy of levofloxacin on macrolide-unresponsive and corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children. Ann Palliat Med. 2019;8(5):632\u20139.","journal-title":"Ann Palliat Med"},{"issue":"10","key":"13433_CR6","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/jcm11102824","volume":"11","author":"L Tong","year":"2022","unstructured":"Tong L, Huang S, Zheng C, Zhang Y, Chen Z. Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management. J Clin Med. 2022;11(10):2824.","journal-title":"J Clin Med"},{"issue":"1","key":"13433_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","volume":"333","author":"World Medical Association","year":"2025","unstructured":"World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human participants. JAMA. 2025;333(1):71\u20134.","journal-title":"JAMA"},{"issue":"1","key":"13433_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12879-020-05356-1","volume":"20","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wang J, Chen W, Shen N, Tao Y, Zhao R, Luo L, Li B, Cao Q. Impact of viral coinfection and macrolide-resistant Mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2020;20(1):633.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"13433_CR9","doi-asserted-by":"publisher","first-page":"ofab628","DOI":"10.1093\/ofid\/ofab628","volume":"9","author":"DS Dodson","year":"2022","unstructured":"Dodson DS, Heizer HR, Gaensbauer JT. Sequential intravenous-oral therapy for pediatric streptococcus anginosus intracranial infections. Open Forum Infect Dis. 2022;9(1):ofab628.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"13433_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s15010-021-01709-3","volume":"50","author":"JA Al-Tawfiq","year":"2022","unstructured":"Al-Tawfiq JA, Momattin H, Al-Ali AY, Eljaaly K, Tirupathi R, Haradwala MB, Areti S, Alhumaid S, Rabaan AA, Al Mutair A, Schlagenhauf P. Antibiotics in the pipeline: a literature review (2017\u20132020). Infection. 2022;50(3):553\u201364.","journal-title":"Infection"},{"issue":"22","key":"13433_CR11","first-page":"1757","volume":"35","author":"Z Yao Xiali","year":"2020","unstructured":"Yao Xiali Z, Rui JXZ, Xiaojian D, Shuzhang Y, Zhao. Research progress on clinical use of ciprofloxacin and levofloxacin in minors. Chin J Practical Pediatr. 2020;35(22):1757\u201360.","journal-title":"Chin J Practical Pediatr"},{"issue":"10","key":"13433_CR12","first-page":"764","volume":"38","author":"B Liu Xiaohui","year":"2023","unstructured":"Liu Xiaohui B, Jing Z, Yafang X. Application of levofloxacin in pediatric clinical practice. Chin J Practical Pediatr Clin Pract. 2023;38(10):764\u201367.","journal-title":"Chin J Practical Pediatr Clin Pract"},{"issue":"3","key":"13433_CR13","first-page":"e1671","volume":"28","author":"JC Gardner","year":"2022","unstructured":"Gardner JC, Courter JD, Dandoy CE, et al. Safety and efficacy of prophylactic levofloxacin in pediatric and adult hematopoietic stem cell transplantation patients[J]. Transpl Cell Ther. 2022;28(3):e1671\u20135.","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"13433_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/08880018.2024.2353888","volume":"41","author":"J Koo","year":"2024","unstructured":"Koo J, Hord J, Gilliam C, Davies SM, Teusink-Cross A. Levofloxacin prophylaxis in pediatric oncology and hematopoietic stem cell transplantation: a literature review. Pediatr Hematol Oncol. 2024;41(6):432\u201348.","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"13433_CR15","doi-asserted-by":"publisher","first-page":"e28643","DOI":"10.1002\/pbc.28643","volume":"67","author":"B Maser","year":"2020","unstructured":"Maser B, Pelland-Marcotte MC, Alexander S, Sung L, Gupta S. Levofloxacin prophylaxis in hospitalized children with leukemia: a cost-utility analysis. Pediatr Blood Cancer. 2020;67(10):e28643.","journal-title":"Pediatr Blood Cancer"},{"issue":"24","key":"13433_CR16","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","volume":"391","author":"AC Hesseling","year":"2024","unstructured":"Hesseling AC, Purchase SE, Martinson NA, Fairlie L, Schaaf HS, Brigden J, Staples S, Gibb DM, Garcia-Prats A, Conradie F, McGowan C, Layton C, Batist E, Demers AM, Nyamathe S, Frigati L, Turner R, Duong T, Seddon JA. Levofloxacin preventive treatment in children exposed to MDR tuberculosis. N Engl J Med. 2024;391(24):2315\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"13433_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S2352-4642(24)00330-4","volume":"9","author":"AJ Garcia-Prats","year":"2025","unstructured":"Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D\u2019Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, endTB Study Group, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Vel\u00e1squez GE, Williams B, Yim JJ, Savic R, Hesseling A. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025;9(2):100\u201311.","journal-title":"Lancet Child Adolesc Health"},{"key":"13433_CR18","doi-asserted-by":"publisher","first-page":"1381742","DOI":"10.3389\/fped.2024.1381742","volume":"12","author":"Z Junqi","year":"2024","unstructured":"Junqi Z, Jie C, Jinglin W, Jinmiao L, Guoping L, Yi W, Zhiping L. A retrospective study of the efficacy and safety of levofloxacin in children with severe infection. Front Pediatr. 2024;12:1381742.","journal-title":"Front Pediatr"},{"issue":"1","key":"13433_CR19","first-page":"35","volume":"56","author":"C LevofloxacCarbon","year":"2001","unstructured":"LevofloxacCarbon C. Tol\u00e9rance de la l\u00e9vofloxacine, dossier clinique et donn\u00e9es de pharmacovigilance [Levofloxacin adverse effects, data from clinical trials and pharmacovigilance]. Therapie. 2001;56(1):35\u201340.","journal-title":"Therapie"},{"issue":"6","key":"13433_CR20","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1097\/MJT.0000000000001615","volume":"30","author":"A Kumabe","year":"2023","unstructured":"Kumabe A, Kenzaka T. Levofloxacin-associated encephalopathy. Am J Ther. 2023;30(6):e549\u201350.","journal-title":"Am J Ther"},{"issue":"3","key":"13433_CR21","first-page":"126","volume":"48","author":"RF Palma-Alvarez","year":"2020","unstructured":"Palma-Alvarez RF, Duque-Yemail J, Ros-Cucurull E, Robles-Mart\u00ednez M, Perea-Ortueta M, Grau-L\u00f3pez L, Ramos-Quiroga JA. Quinolone-induced psychosis: an updated review. Actas Esp Psiquiatr. 2020;48(3):126\u201337.","journal-title":"Actas Esp Psiquiatr"},{"issue":"6","key":"13433_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/nep.12405","volume":"20","author":"Y Liu","year":"2015","unstructured":"Liu Y, He Q, Wu M. Levofloxacin-induced crystal nephropathy. Nephrol (Carlton). 2015;20(6):437\u20138.","journal-title":"Nephrol (Carlton)"},{"issue":"12","key":"13433_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5414\/CP204377","volume":"61","author":"M Wu","year":"2023","unstructured":"Wu M, Yang D. Levofloxacin-induced acute rhabdomyolysis: a case report. Int J Clin Pharmacol Ther. 2023;61(12):572\u20134.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"13433_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jemermed.2012.09.027","volume":"45","author":"G Guti\u00e9rrez-Guti\u00e9rrez","year":"2013","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez G, Sereno M, Garc\u00eda Vaquero C, Miralles A. Levofloxacin-induced myastheniccrisis. J Emerg Med. 2013;45(2):260\u20131.","journal-title":"J Emerg Med"},{"issue":"8","key":"13433_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.ad.2018.04.010","volume":"110","author":"M Castellanos-Gonz\u00e1lez","year":"2019","unstructured":"Castellanos-Gonz\u00e1lez M, Gonz\u00e1lez Morales ML, Gonz\u00e1lez-Granda Villalobos J. Levofloxacin-Induced Hyperpigmentation. Actas Dermosifiliogr (Engl Ed). 2019;110(8):700\u20131.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"12","key":"13433_CR26","doi-asserted-by":"publisher","first-page":"e252052","DOI":"10.1136\/bcr-2022-252052","volume":"15","author":"M Francesco","year":"2022","unstructured":"Francesco M, Joshua B, Mark KS, Imama AN. Levofloxacin-associated transient mixed sensorimotor lacunar syndrome. BMJ Case Rep. 2022;15(12):e252052.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"13433_CR27","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1542\/peds.2013-3636","volume":"134","author":"JS Bradley","year":"2014","unstructured":"Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014;134(1):e146\u201353.","journal-title":"Pediatrics"},{"issue":"5","key":"13433_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40272-022-00513-2","volume":"24","author":"S Li","year":"2022","unstructured":"Li S, Chen Z, Huang L, Liu Z, Shi Y, Zhang M, Li H, Zeng L, Ni J, Zhu Y, Jia ZJ, Cheng G, Zhang L. Safety of quinolones in children: a systematic review and meta-analysis. Paediatr Drugs. 2022;24(5):447\u201364.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"13433_CR29","doi-asserted-by":"publisher","first-page":"105064","DOI":"10.1016\/j.idnow.2025.105064","volume":"55","author":"AP Jonville-B\u00e9ra","year":"2025","unstructured":"Jonville-B\u00e9ra AP, Largeau B, di Meglio F, Pariente A. The safety profile of fluoroquinolones. Infect Dis Now. 2025;55(4):105064.","journal-title":"Infect Dis Now"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13433-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:18:58Z","timestamp":1781662738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13433-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13433"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13433-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Weifang people\u2019s Hospital (KYLL20240105-8). All parents or guardians of children participating in the testing signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1157"}}